The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics Inc. released three year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab in first line recurrent or metastatic HPV negative head and neck squamous cell carcinoma (HNSCC).
The Phase 1b dataset, which included approximately 90 patients across three dosing regimens, indicated that deep responses seen in participants were sustained over the long term. The announcement was made during the ASCO26 medical conference and is seen as a significant development in immuno-oncology for this hard-to-treat patient group. Additional data and further analysis may be needed to assess broader clinical implications.
View post on X Loading...
Bicara Therapeutics previously announced ficerafusp alfa as the first EGFR-directed antibody-TGF-beta trap for HPV-negative HNSCC. The company also launched the FORTIFI clinical trial targeting first-line recurrent or metastatic HPV-negative HNSCC patients. Both initiatives reflect Bicara’s focus on addressing unmet medical needs in this patient population.